Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate ( ADC ) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonal antibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors [1] [2].
In Vitro, Elfetabart drozuntecan exhibits favorable anti-tumor activity and safety in solid tumors[1].
References:
[1]. Guo Y, et al. 1017eTiP A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors. Annals of Oncology. 2025 Sep 1;36:S662.
[2]. Cheng Y, et al. Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors. Cancer Research. 2024 Apr 5;84(7_Supplement):CT165-.
In Vitro, Elfetabart drozuntecan exhibits favorable anti-tumor activity and safety in solid tumors[1].
References:
[1]. Guo Y, et al. 1017eTiP A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors. Annals of Oncology. 2025 Sep 1;36:S662.
[2]. Cheng Y, et al. Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors. Cancer Research. 2024 Apr 5;84(7_Supplement):CT165-.